Oral therapeutic - IntelGenx/Par Pharmaceutical

Drug Profile

Oral therapeutic - IntelGenx/Par Pharmaceutical

Latest Information Update: 16 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IntelGenx Corp.; Par Pharmaceutical Inc
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Unspecified

Most Recent Events

  • 05 Nov 2015 Par Pharmaceutical Inc has been acquired by Endo International
  • 31 Mar 2012 Clinical trials in Undefined indication in Canada (PO)
  • 21 Dec 2011 Investigation in Undefined indication in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top